| Literature DB >> 27696820 |
Carlos Ramon Nascimento Brito1, Craig S McKay2, Maíra Araújo Azevedo1, Luíza Costa Brandão Santos1, Ana Paula Venuto1, Daniela Ferreira Nunes1, Daniella Alchaar D'Ávila1, Gisele Macedo Rodrigues da Cunha1, Igor Correia Almeida3, Ricardo Tostes Gazzinelli1, Lucia Maria Cunha Galvão1, Egler Chiari1, Carlos A Sanhueza2, M G Finn2, Alexandre Ferreira Marques1.
Abstract
The α-Gal antigen [Galα(1,3)Galβ(1,4)GlcNAcα] is an immunodominant epitope displayed by infective trypomastigote forms of Trypanosoma cruzi, the causative agent of Chagas disease. A virus-like particle displaying a high density of α-Gal was found to be a superior reagent for the ELISA-based serological diagnosis of Chagas disease and the assessment of treatment effectiveness. A panel of sera from patients chronically infected with T. cruzi, both untreated and benznidazole-treated, was compared with sera from patients with leishmaniasis and from healthy donors. The nanoparticle-α-Gal construct allowed for perfect discrimination between Chagas patients and the others, avoiding false negative and false positive results obtained with current state-of-the-art reagents. As previously reported with purified α-Gal-containing glycosylphosphatidylinositol-anchored mucins, the current study also showed concentrations of anti-α-Gal IgG to decrease substantially in patients receiving treatment with benznidazole, suggesting that the semiquantitative assessment of serum levels of this highly abundant type of antibody can report on disease status in individual patients.Entities:
Keywords: Chagas disease; ELISA; Trypanosoma cruzi; anti-α-Gal antibodies; diagnostics; treatment assessment; α-Gal
Mesh:
Substances:
Year: 2016 PMID: 27696820 DOI: 10.1021/acsinfecdis.6b00114
Source DB: PubMed Journal: ACS Infect Dis ISSN: 2373-8227 Impact factor: 5.084